Phaseline

Targets › CMV

CMV: drug programs, companies and trials

4 programs from 4 companies in 11 trials: 5 Phase 2, 5 Phase 1, 1 Phase 3; Infectious disease, Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on CMV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tobias FeuchtingerMultivirus (CMV, EBV, AdV)-specific T cells
Adoptive transfer of multivirus-specific T cells targeting CMV, EBV, and AdV
CMV, EBV, ADVPhase 3AdV InfectionMar 2028
City of Hope Medical CenterMulti-peptide CMV-Modified Vaccinia Ankara Vaccine
MVA-vectored vaccine expressing CMV peptides; induces immunity to CMV antigens
CMVPhase 2Acute Lymphoblastic Leukemia; Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Cytomegaloviral Infection; Accelerated Phase CML, BCR-ABL1 Positive …Dec 2026
ModernaTXmRNA-1647
mRNA vaccine expressing CMV antigens
CMVPhase 2Cytomegalovirus InfectionMar 2027
The Methodist Hospital Research InstituteValganciclovir
Human herpesvirus 1 DNA polymerase inhibitor
CMVPhase 2Brain Cancer MetastaticMay 2028

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (2) Cytomegalovirus Infection (1) AdV Infection (1) Acute Lymphoblastic Leukemia (1) Cytomegaloviral Infection (1) Accelerated Phase CML, BCR-ABL1 Positive (1) B-Cell Non-Hodgkin Lymphoma (1) High Grade B-Cell Non-Hodgkin's Lymphoma (1) Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive (1) Brain Cancer Metastatic (1)

Modalities

other (2), small molecule (1)

Companies

ModernaTX (1) Tobias Feuchtinger (1) City of Hope Medical Center (1) The Methodist Hospital Research Institute (1)

Related targets

EBV (1) ADV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.